Deutsche Bank AG Boosts Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Deutsche Bank AG grew its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 11.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 272,973 shares of the company’s stock after buying an additional 28,556 shares during the quarter. Deutsche Bank AG’s holdings in Privia Health Group were worth $5,337,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Durable Capital Partners LP lifted its holdings in shares of Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock valued at $224,587,000 after acquiring an additional 378,255 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Privia Health Group by 5.1% during the fourth quarter. Bank of America Corp DE now owns 1,021,763 shares of the company’s stock worth $19,975,000 after purchasing an additional 49,389 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Privia Health Group during the fourth quarter worth about $4,321,000. Algert Global LLC boosted its position in shares of Privia Health Group by 639.1% in the fourth quarter. Algert Global LLC now owns 108,048 shares of the company’s stock worth $2,112,000 after buying an additional 93,429 shares during the period. Finally, Alyeska Investment Group L.P. boosted its position in shares of Privia Health Group by 20.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 300,000 shares of the company’s stock worth $5,865,000 after buying an additional 50,000 shares during the period. Institutional investors and hedge funds own 94.48% of the company’s stock.

Privia Health Group Price Performance

PRVA opened at $25.02 on Monday. Privia Health Group, Inc. has a 12-month low of $15.92 and a 12-month high of $26.09. The stock has a market capitalization of $3.05 billion, a PE ratio of 250.23, a P/E/G ratio of 3.47 and a beta of 0.87. The firm’s fifty day moving average price is $23.36 and its 200 day moving average price is $22.57.

Analyst Upgrades and Downgrades

PRVA has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Privia Health Group in a report on Thursday, April 10th. Robert W. Baird lifted their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday, April 15th. Canaccord Genuity Group boosted their target price on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Truist Financial upped their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Finally, Barclays lifted their price target on shares of Privia Health Group from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $27.38.

Insider Transactions at Privia Health Group

In other Privia Health Group news, Director Matthew Shawn Morris sold 10,309 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $240,508.97. Following the sale, the director now owns 59,792 shares in the company, valued at $1,394,947.36. This represents a 14.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO David Mountcastle sold 3,322 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $24.99, for a total value of $83,016.78. Following the transaction, the chief financial officer now directly owns 172,909 shares in the company, valued at approximately $4,320,995.91. This represents a 1.89% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,579 shares of company stock valued at $1,226,367. Insiders own 10.70% of the company’s stock.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.